Trial-Results center  
Clinical trial results database Feedback    Home

This trial is included in the following systematic reviews and meta-analyses:

acute myocardial infarction - myocardial revascularization - all type of patients  


Related trials

ZEST AMI (vs SES), 2009 - zotarolimus ES vs sirolimus ES

TRIANA, 2009 - primary ballon angioplasty vs tenecteplase

NORDISTEMI, 2009 - thrombolysis + angioplasty vs immediate thrombolysis

Juwana, 2009 - sirolimus ES vs paclitaxel ES

ZEST AMI (vs PES), 2009 - zotarolimus ES vs paclitaxel ES

PASEO, 2009 - drug ES vs bare-metal stent

CARESS, 2008 - thrombolysis + angioplasty vs immediate thrombolysis

HORIZONS-AMI Stent, 2008 - paclitaxel ES vs bare-metal stent

MISSION, 2008 - sirolimus ES vs bare-metal stent

DEDICATION, 2008 - drug ES vs bare-metal stent

Díaz de la Llera, 2007 - sirolimus ES vs bare-metal stent

SESAMI, 2007 - sirolimus ES vs bare-metal stent

TYPHOON, 2006 - sirolimus ES vs bare-metal stent

PROSIT, 2006 - sirolimus ES vs paclitaxel ES

HAAMU-STENT, 2006 - paclitaxel ES vs bare-metal stent

PASSION, 2006 - paclitaxel ES vs bare-metal stent

WEST, 2006 - systematic PCI (+stent) vs no systematic PCI

CAPITAL AMI, 2005 - thrombolysis + angioplasty vs immediate thrombolysis

Di Lorenzo et al., 2005 - sirolimus ES vs paclitaxel ES

ZWOLLE 6, 2005 - primary stenting vs ballon angioplasty

CAPITAL AMI, 2005 - systematic PCI (+stent) vs no systematic PCI

senior PAMI, 2005 - primary PCI vs thrombolytic therapy

STOPAMI 3, 2004 - primary stenting vs ballon angioplasty

GRACIA-1, 2004 - systematic PCI (+stent) vs no systematic PCI

MERLIN (Sutton), 2004 - immediate systematic ballon angioplastyte vs no immediate angioplasty



See also:

  • All acute myocardial infarction clinical trials
  • All clinical trials of myocardial revascularization
  • All clinical trials of Prehospital thrombolysis
    		•  

    EMIP study, 1993

    Treatments

    Studied treatment anistreplase by mobile intensive care unit
    Control treatment
    Treatments description
    Thrombolytic agent Anistreplase 
    Time from sympton onset to thrombolysis median 130/190 min 
    Provider MICU 

    Patients

    Inclusion criteria Chest pain duration from 30 min to <6 h from symptom onset or chest pain <30 min and not responding to nitrates Patients stratified by ECG changes into ST-segment elevation group (at least 2.0 mm in at least 2 precordial leads, at least 1 mm in 2 limb leads, or both) or no ST-segment elevation group (QRS >0.12 s or isolated ST-segment level depression or tall T-waves with coronary artery disease)
    Exclusion criteria Use of oral anticoagulants (antiplatelet allowed), hemorrhagic diasthesis, pyloric ulcer disease, stroke, surgery or major trauma <6 mo previously, external cardiac massage, SBP >200 mm Hg and/or DBP >120 mm Hg, pregnancy, coronary angioplasty less than 2 wk prior, no consent, withdrawal at the discretion of the investigator

    Method and design

    Randomized effectives 2750 / 2719 (studied vs. control)
    Blinding ND
    Follow-up duration ND
    Lost to follow-up ND
    Withdrawals (T1/T0) ND /


    Results

    Endpoint Studied treat.
    n/N     Control treat.
    n/N     Graph RR [95% CI]

    All cause death

    251 / 2750
         284 / 2719
         0,87 [0,74;1,03]     0 2 1.0

    Relative risks
    Endpoint Events (%) Relative Risk 95% CI Endpoint definition
    in the trial    		 Ref
    Studied treat. Control treat.
    All cause death 251 / 2750 (9,1%) 284 / 2719 (10,4%) 0,87 [0,74;1,03]    
    The primary endpoint (if exists) appears in blod characters
    Reference(s) used for data extraction:

    Endpoint studied treat. control treat. mean diff

    Absolute risk reduction
    Endpoint Events rate Absolute risk
    reduction (ARR)
    Studied treat. Control treat.
    All cause death 9,13% 10,45% -13,2‰


    Reference(s)

    Trials register # NA
    • ,. Prehospital thrombolytic therapy in patients with suspected acute myocardial infarction. The European Myocardial Infarction Project Group.. N Engl J Med 1993; 329:383-9
      Pubmed | Hubmed | Fulltext

    (c) 2004-2010 TrialResults-center - All Rights Reserved

    Tweet this  |  notify a friend